Investors & Media

Innovating Bacterial Vaccines at Scale

Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make protein antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. 

With this competitive advantage, VAX-24, Vaxcyte’s lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate being developed for the prevention of invasive pneumococcal disease (IPD) has the potential to be a best-in-class PCV in an already $7 billion global market that is poised to undergo significant growth. VAX-24 was recently granted FDA Breakthrough Therapy designation for the prevention of IPD in adults. Additionally, Vaxcyte’s pipeline includes VAX-31, a 31-valent PCV candidate, VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontitis, and VAX-GI, a novel prophylactic vaccine designed to prevent Shigella. 
 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description View

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

View HTML

Statement of changes in beneficial ownership of securities

View HTML

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

View HTML